Lauxera Capital Partners. (9/12/23). "Press Release: Lauxera Capital Partners Invests €17 Million in Swedish Regenerative Medicine Leader BioLamina AB". Paris & San Francisco, CA.

	Organisation	Lauxera Capital Partners SAS
	Group	Lauxera (Group)
	Organisation 2	BioLamina AB
	Group	BioLamina (Group)
	Product	Biolaminin® substrate
	Product 2	private equity
	Index term	BioLamina–Lauxera: investment, 202309 investment €17m by Lauxera Growth I fund
	Person	Sköld, Veronica Byfield (BioLamina 202308 CEO)
	Person 2	Slack, Alex (Lauxera Capital Partners 202009 Founding Partner)

> Founded in 2009 and based in Sundbyberg, Sweden, BioLamina’s recombinant human laminin proteins are revolutionizing the development and manufacturing of regenerative cell therapeutics and disease models derived from both stem cells and primary cells

> Lauxera is impressed by the company’s development and supports BioLamina’s plan to continue to expand its global footprint, widen its product offerings, and scale its production capacity at multiple quality levels to meet the strong demand from both innovative biopharma players and from life science tools and services companies

Lauxera Capital Partners announced today that it has invested €17 million in BioLamina AB (BioLamina), a Swedish company specializing in the development and commercialization of recombinant proteins supporting the maintenance, expansion, and differentiation of stem cells and primary cells for both research and therapeutic purposes. With the investment, Lauxera Capital Partners is joining with other distinguished investors – majority owner Bure Equity AB, a listed Swedish investment company and long-standing BioLamina shareholder, and Northislet AB, a Swedish investment company in emerging medical technologies – as well as with BioLamina’s founders and executives as shareholders in support of the company’s mission.

BioLamina was founded in 2009 by the father-son team of Drs. Karl Tryggvason and Kristian Tryggvason, based on the breakthrough research of the elder Dr. Tryggvason at the Karolinska Institute and Duke-NUS Medical School. Since then, the company has developed unique expertise in the development and production of recombinant human laminins, which are key proteins enabling researchers and biopharma to grow, manipulate, and engineer both stem cells and certain primary cells. Present in high concentration in human embryonic tissues, BioLamina’s recombinant laminins are fully-defined, process reagents that enable both researchers and therapeutic innovators in the space to mimic and precisely control culture conditions during the production of stem cell-derived therapeutics and advanced cell-based disease models.

Broadest portfolio and highest standard in the market

BioLamina is a leading, independent player feeding the growth of the rapidly-expanding stem cell field. The broad portfolio of recombinant laminin isoforms developed by BioLamina (Biolaminins®) includes both research-grade and cell therapy-grade products, which serve customers from early academic researchers through to leading makers of stem cell-derived therapeutics currently in clinical trials and preparing for commercialization. BioLamina’s products are uniquely produced in human cell lines, yielding attributes which contribute to predictability and reproducibility at the company’s customers. BioLamina’s multi-decade long track record of quality as a producer both of research- and cell therapy-grade reagents is recognized across the industry.

BioLamina supports the revolutionary potential of stem cells in curing and understanding a multitude of human diseases

The field of regenerative, stem cell-derived therapeutics pioneered by BioLamina and by many leading biopharma innovators promises to restore full function for patients suffering from diseases characterized by cell death (e.g., Type 1 diabetes, Parkinson’s disease, heart failure, and many others). While the past two decades have hinted at this potential – with positive clinical results leveraging both cadaveric cells and embryonic stem cells – it is only in the past year that several leading biopharma innovators have delivered proof-of-concept results across multiple diseases which utilize new, more scalable production processes. These recent breakthroughs in the clinic and in process development, both supported by BioLamina, have laid the basis for a new class of regenerative therapeutics that can sustainably replace cells lost to disease.

In addition to their direct therapeutic applications, stem cells are also powering the development of increasingly sophisticated disease models. These models accurately represent disease dynamics across multiple cell types, reducing or replacing the use of live animal models in translational research and development. Combined with the aforementioned advances in therapeutics, this foothold in earlier-stage research will firmly entrench stem cells as a key technology driving medical advances over the coming decades.

BioLamina is well positioned to support the entire stem cell field as the provider of its most critical and widely-validated inputs, methods, expertise, and intellectual property.

Veronica Byfield Sköld, CEO at BioLamina, declared: “The BioLamina team is excited to welcome Lauxera to our committed group of shareholders and to our Board of Directors, and we look forward to leveraging the Lauxera team’s experience and insights into our markets. Throughout the transaction process it has become clear that they share our passion for supporting both academic pioneers and trailblazing biotech visionaries in their quest to provide life-changing solutions.”

Alex Slack, co-founder of Lauxera Capital Partners, added: “The entire team at Lauxera could not be more excited to partner with BioLamina in advancing the stem cell field as it delivers breakthroughs in regenerative medicine and in disease research. BioLamina stands at the fulcrum of inflection points in two attractive end markets, with a strong and dedicated executive team, talented employees, and a convicted investor base. We are humbled by the responsibility to help BioLamina achieve its next leg of growth, adding to and enhancing its global footprint, manufacturing and regulatory capabilities, and customer intimacy.”

This is the tenth investment made by Lauxera Growth I, a growth and growth buy-out fund dedicated to investing primarily in commercial-stage European Healthtech businesses. As part of the investment, Alex Slack, co-founder of Lauxera, will join BioLamina's Board of Directors. Lauxera’s investment team also included Victor Decrion (Partner), Charles Cornevin (Principal) and Alessandra Petiot (Associate).

Alvarez & Marsal carried out the financial due diligence, Goodwin Procter LLP managed intellectual property, and the Swedish law firm Cirio Advokatbyrå AB acted as legal advisor. Dark Horse Consulting and BDO Global supported Lauxera in its commercial, manufacturing, and regulatory due diligence.

***

About Lauxera Capital Partners

Founded in January 2020, Lauxera Capital Partners is an independent asset management company based in France (Paris) and in the United States (San Francisco). Lauxera is a healthcare specialist investor working to promote the growth of European Healthtech companies. Its first fund, Lauxera Growth I, was reserved for professional investors and obtained the French government's “Tibi” label within the framework of the institutional investors’ charter for the financing of technology companies. Led by a team of life sciences business builders and professional healthcare investors with more than 50 years experience, Lauxera aims to support the international commercial expansion of Europe's most promising Healthtech innovations. More information at: https://lauxera.com

About BioLamina

BioLamina is a biotechnology company with a scientific base and heritage in matrix biology and cell culture research. It supports scientists who have struggled for decades to grow embryonic stem cells, induced pluripotent stem (iPS) cells and other primary cells. By providing tools for efficient and easy culture, BioLamina aims to ease the path towards safe and effective cell therapy. The power of Biolaminin® substrates, developed by BioLamina, has been demonstrated in numerous publications, and they will continue to provide vital support to the stem cell community - from scientific concepts to clinical studies. Based in Sundbyberg (Sweden), the company currently employs 70 people. The company’s main shareholders include Bure Equity AB (via Bure Growth), the Tryggvason family (founders), Northislet AB, and Lauxera Capital Partners. Further information: https://biolamina.com

Press contacts:

Ulysse Communication

Bruno ARABIAN
+33 (0) 6 87 88 47 26 barabian@ulysse-communication.com

Pierre-Louis GERMAIN
+33 (0)6 64 79 97 51 plgermain@ulysse-communication.com

Record changed: 2024-01-20

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)